RadioMedix
St. Louis, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $40M
Overview
A biotech developing and commercializing targeted radiopharmaceuticals for cancer diagnosis and therapy.
OncologyRare Disease
Technology Platform
A platform for developing peptide-targeted radiopharmaceuticals (theranostics) that combine diagnostic imaging and therapeutic radiation for cancer.
Funding History
1Total raised:$40M
Venture$40M
Opportunities
Significant unmet need in neuroendocrine and other hard-to-treat cancers, with a validated theranostics approach gaining broader adoption.
Risk Factors
Faces complex regulatory, manufacturing, and logistical hurdles inherent to radiopharmaceuticals, and competition from large pharma.
Competitive Landscape
A well-positioned player in the competitive but high-growth radiopharmaceutical theranostics market, with a late-stage asset.